Kestra Medical posts 60% revenue growth and lifts long-term margin guidance, fueled by strong adoption of its cardiac recovery system and expanding market access.
Kestra reported strong Q1 results with 60% revenue growth and raised gross margin targets, indicating bullish momentum.
Kestra Medical Technologies reported a strong first quarter for fiscal 2027, with revenue climbing 60% year-over-year to $31 million. The company also raised its long-term gross margin target to the mid-70s, citing consistent operational leverage and successful market penetration of its ASSURE WCD platform.
Kestra attributes its margin expansion to consistent volume leverage, operational efficiencies, and a growing in-network payer mix, which has improved from 70% at IPO to over 80%.